验证预测rtPA后出血转化的临床-遗传学评分
本研究在西班牙和芬兰的1,482例接受rtPA治疗的卒中患者中验证Genot-PA评分,该评分基于临床和遗传因素通过逻辑回归构建,用于分层溶栓治疗安全性。结果显示,在完成评分的1,324例患者中,213例(16.1%)发生出血转化,85例(6.4%)发生实质性血肿;Genot-PA评分可预测出血转化,并在探索性分析中与机械取栓患者的实质性血肿风险相关。
要点
- Genot-PA评分可预测静脉rtPA治疗卒中患者的出血转化风险。
- 评分最高风险组的实质性血肿风险显著升高。
- 在机械取栓患者中评分与实质性血肿风险的关联为探索性发现。
核心结论
- Genot-PA评分可预测接受静脉rtPA治疗的卒中患者的出血转化。
- 在探索性研究中,该评分与机械取栓治疗患者的实质性血肿风险相关。
研究设计与样本
- 研究纳入2003至2016年西班牙和芬兰的1,482例接受rtPA治疗的卒中患者。
- 按种族和治疗方式分为队列A、B、C(西班牙)和D(芬兰),共1,324例完成评分计算。
主要发现
- 1,324例完成评分患者中,213例(16.1%)发生出血转化,85例(6.4%)发生实质性血肿。
- 在队列A、B、D中,评分可预测出血转化(p=2.02×10-6,p=0.023,p=0.033)。
- 在队列A至C中,评分与实质性血肿相关(p=0.012,p=0.034,p=5.32×10-4)。
- 实质性血肿频率从最低风险组到最高风险组增加:队列A 4%-15.7%,队列B 1.5%-18.2%,队列C 0%-100%。
- 队列A最高风险组预测实质性血肿的比值比为5.16(95%CI 1.46-18.08,p=0.009)。
临床怎么用
- Genot-PA评分可用于评估静脉rtPA治疗后出血转化风险,辅助临床决策。
局限性
- 在机械取栓患者中的发现为探索性研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate the Genot-PA score, a clinical-genetic logistic regression score that stratifies the thrombolytic therapy safety, in a new cohort of patients with stroke. METHODS: We enrolled 1,482 recombinant tissue plasminogen activator (rtPA)-treated patients with stroke in Spain and Finland from 2003 to 2016. Cohorts were analyzed on the basis of ethnicity and therapy: Spanish patients treated with IV rtPA within 4.5 hours of onset (cohort A and B) or rtPA in combination with mechanical thrombectomy within 6 hours of onset (cohort C) and Finnish participants treated with IV rtPA within 4.5 hours of onset (cohort D). The Genot-PA score was calculated, and hemorrhagic transformation (HT) and parenchymal hematoma (PH) risks were determined for each score stratum. RESULTS: Genot-PA score was tested in 1,324 (cohort A, n = 726; B, n = 334; C, n = 54; and D, n = 210) patients who had enough information to complete the score. Of these, 213 (16.1%) participants developed HT and 85 (6.4%) developed PH. In cohorts A, B, and D, HT occurrence was predicted by the score (p = 2.02 × 10-6, p = 0.023, p = 0.033); PH prediction was associated in cohorts A through C (p = 0.012, p = 0.034, p = 5.32 × 10-4). Increased frequency of PH events from the lowest to the highest risk group was found (cohort A 4%-15.7%, cohort B 1.5%-18.2%, cohort C 0%-100%). The best odds ratio for PH prediction in the highest-risk group was obtained in cohort A (odds ratio 5.16, 95% confidence interval 1.46-18.08, p = 0.009). CONCLUSION: The Genot-PA score predicts HT in patients with stroke treated with IV rtPA. Moreover, in an exploratory study, the score was associated with PH risk in mechanical thrombectomy-treated patients.
引用
- Carrera C, Cullell N, Torres-Águila N, et al. Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. Neurology. 2019. PMID: 31366724. doi:10.1212/WNL.0000000000007997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。